Cargando…

Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation

Single nucleotide polymorphisms in drug-metabolizing genes may affect tacrolimus pharmacokinetics. Here, we investigated the influence of genotypes of CYP3A5, CYP2C19, and POR on the concentration/dose (C/D) ratio of tacrolimus and episodes of acute graft-versus-host disease (GVHD) in Japanese recip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suetsugu, Kimitaka, Mori, Yasuo, Yamamoto, Nanae, Shigematsu, Tomohiro, Miyamoto, Toshihiro, Egashira, Nobuaki, Akashi, Koichi, Masuda, Satohiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566597/ https://www.ncbi.nlm.nih.gov/pubmed/31096684 http://dx.doi.org/10.3390/ijms20102413

Ejemplares similares

Influence of POR*28 Polymorphisms on CYP3A5*3-Associated Variations in Tacrolimus Blood Levels at an Early Stage after Liver Transplantation
por: Nakamura, Takahiro, et al.
Publicado: (2020)

Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients
por: Zhang, Mengyu, et al.
Publicado: (2020)

Neutrophil Gelatinase-Associated Lipocalin Is Not Associated with Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients Who Received Mycophenolate Mofetil with Delayed Introduction of Tacrolimus
por: Fukuda, Mio, et al.
Publicado: (2019)

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021)

Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation
por: Uchida, Mayako, et al.
Publicado: (2013)

CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients
por: Yamamoto, Yuki, et al.
Publicado: (2020)

Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis
por: Kim, Jung Sun, et al.
Publicado: (2023)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion
por: Yoshikawa, Naoki, et al.
Publicado: (2021)

Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients
por: Li, Chuan-Jiang, et al.
Publicado: (2014)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities
por: Zhang, Wei, et al.
Publicado: (2019)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation
por: Moes, D J A R, et al.
Publicado: (2014)

Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influences on tacrolimus dose adjusted concentration in adult heart transplant recipients
por: Hernandez, Savine, et al.
Publicado: (2023)

Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events
por: Matsukane, Ryosuke, et al.
Publicado: (2021)

Preferential expression of cytochrome CYP CYP2R1 but not CYP1B1 in human cord blood hematopoietic stem and progenitor cells
por: Xu, Shuoqi, et al.
Publicado: (2014)

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
por: Li, Min, et al.
Publicado: (2018)

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living‐donor Egyptian kidney transplanted patients
por: Wanas, Hanaa, et al.
Publicado: (2023)

Relationship between incident types and impact on patients in drug name errors: a correlational study
por: Tsuji, Toshikazu, et al.
Publicado: (2015)

Evaluation of clotrimazole prophylaxis on tacrolimus trough concentrations in kidney transplant recipients
por: Wings, Emily, et al.
Publicado: (2022)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
por: Buendía, Jefferson Antonio, et al.
Publicado: (2020)

Effects of CYP3A5 Genotypes on Thrombocytopenia in Liver Transplantation Patients Treated with Tacrolimus
por: Guo, Zhe, et al.
Publicado: (2023)

The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients
por: Hiraoka, Sakiko, et al.
Publicado: (2015)

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
por: Okabayashi, Shinji, et al.
Publicado: (2019)

Effect of CYP3A5 on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients
por: Kim, Jong Man, et al.
Publicado: (2020)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients
por: Déri, Máté, et al.
Publicado: (2021)

Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?
por: Chavant, Anaelle, et al.
Publicado: (2021)

Differences in recognition of similar medication names between pharmacists and nurses: a retrospective study
por: Tsuji, Toshikazu, et al.
Publicado: (2015)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation
por: Yamashita, Takaya, et al.
Publicado: (2016)

Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques
por: UNO, Yasuhiro, et al.
Publicado: (2014)

Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients
por: Zhu, Jing, et al.
Publicado: (2020)

A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
por: Liu, Yuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qdihcmtdplqet1mt3k67v8j35d